Redcare Pharmacy stock: MPCM lifts target to 125 euros

Published on 11/09/2026 at 17:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

MPCM kept its Buy rating after the November 3 analyst action. Redcare Pharmacy stock enters the final quarter with its 2026 outlook unchanged.

Analyst target and growth outlook

MPCM raised its target while keeping its Buy rating unchanged.
Third-quarter revenue grew 18 percent and adjusted EBITDA margin reached 3.4 percent.
Management maintained its full-year revenue growth outlook of 16 to 18 percent.

Redcare Pharmacy, NL0012044747, Illustration mit AI erstellt.

MPCM raised its price target for Redcare Pharmacy from 120 to 125 euros on November 3 and kept its Buy rating unchanged, according to Boerse Express. The analyst action changes the valuation marker without changing the stated recommendation.

Redcare Pharmacy stock traded at 72.70 euros on Lang & Schwarz at 17:13 CET on Monday, November 9, 3.05 percent above the Xetra close of Friday, November 6. The move leaves the shares below both the revised MPCM target and Jefferies' unchanged 97-euro target.

Operating progress supports the debate

Redcare Pharmacy reported third-quarter revenue of 846.7 million euros, an increase of 18 percent from the prior-year quarter. Adjusted EBITDA margin reached 3.4 percent, up 1.0 percentage point year on year, according to Boerse Express.

Management maintained its 2026 revenue growth outlook of 16 to 18 percent. The company also reported more than 15 million active customers in Europe and a repeat-order rate above 90 percent in the third quarter.

The analyst split leaves investors focused on execution rather than on a uniform reassessment of the business. MPCM's higher target contrasts with Jefferies' unchanged target, while prescription growth, customer retention and operating leverage remain central to the investment case.